<DOC>
	<DOCNO>NCT00948077</DOCNO>
	<brief_summary>The purpose study evaluate effect food pharmacokinetic profile multiple dose orally administer first-line anti-tuberculosis drug subject pulmonary tuberculosis .</brief_summary>
	<brief_title>Pharmacokinetic Study Anti-tuberculosis Drugs</brief_title>
	<detailed_description>This single-center , open-label , randomize , two way crossover design , pharmacokinetics study . 1 . Treatment A : study agent ( Rifater+EMB ) give approximately 45 minute prior breakfast . 2 . Treatment B : study agent ( Rifater+EMB ) give approximately 45 minute breakfast finish .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Isoniazid , pyrazinamide , rifampin drug combination</mesh_term>
	<criteria>1 . Age great 20 year 2 . Karnofsky score &gt; 50 3 . Clinical radiographic sign symptom consistent pulmonary TB determine investigator . 4 . A documented positive microbiology diagnosis result indicate highly suspect pulmonary tuberculosis . 5 . AntiTB drug treatment ethambutol , isoniazid , rifampin pyrazinamide . 6 . Willing hospitalize per standard care least 6 day first antiTB drug administer . 7 . Start antiTB chemotherapy least 2 day prior participate study . 8 . The subject able understand comply protocol requirement , follow instruction protocolstated restriction . 9 . Only subject provide sign dated write informed consent include . 1 . Previously treat MDRTB , XDRTB likely require surgical procedure management TB 2 . Alcohol drug abuse would interfere ability meet study requirement ( opinion investigator ) 3 . Concomitant disorder condition ethambutol , isoniazid , rifampin pyrazinamide contraindicate . 4 . Unable meet select safety criterion obtain screening ( Laboratory parameter , etc . ) 5 . Women Pregnant breastfeed study period . 6 . Subjects know allergy study drug 7 . In opinion investigator unsuitable study participation reason .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>first-line drug</keyword>
</DOC>